eISSN: 2867-1955 pISSN: 1305-2489
  • Home
  • The effect of intracavernosal alprostadil use in erectile dysfunction second line treatment on sexual functions

Original Research

The effect of intracavernosal alprostadil use in erectile dysfunction second line treatment on sexual functions


1 Necmettin Erbakan University, Meram Medical Faculty, Department of Urology, Konya, Turkey

ABSTRACT

Objective: In patients treated through the application of intracavernosal alprostadil in sec-ond-line treatment due to erectile dysfunction, the effect of the treatment on sexual functions measured with a 15-question International Index of Erectile Function (IIEF-15) questionnaire was investigated in this study.

Material and Methods: Twenty-one patients treated due to erectile dysfunction between June 2018-October 2019, taking inadequate response from first-line treatment modalities, were applied intracavernosal alprostadil in second-line treat-ment and continued it for more than 12 weeks were included in the study, retrospectively. Ages, comorbid diseases, drug usage duration, drug-re-lated side effects, penile Doppler ultrasonography (USG) parameters before application and the erec-tion functions before and 12 weeks after drug use were evaluated with IIEF-15 form for the patients. Intracavernosal alprostadil was started with a dose of 5 μg and was continued with a dose of 10 μg as the result of dose titration.

Results: The mean peak systolic blood flow velocity (PS) value of the patients was 24.4 ±15.1 cm/sec, and the mean end-diastolic flow veloc-ity (ED) value was measured as 4.3±4.5 cm/sec based on the pre-treatment penile Doppler USG. Although the IIEF scores were measured in the 12th week, mean drug usage durations were mea-sured as 21.9±16.6 weeks. Erectile Function Score was 9.2±5.3 before application; it was detected as 20.33±6.2 after the application. Orgasmic Func-tion Score was 3.2±2.5 before application; it was detected as 7.5±2.4 after the application. Sexual Desire Score was 3.72±1.48 before application; it was detected as 8.9±1.4 after the application. Intercourse Satisfaction Score was 3.7±2.8 before appli-cation; it was detected as 9.1±2.7 after the application. Overall Satis-faction Score was 4±1.7 before application; it was detected as 8.1±1.7 after the application (All parameters p<0.001).

Conclusion: Intracavernosal alprostadil treatment used in erectile dysfunction second-line treatment is a cost-effective and efficient treatment method with a tolerable side effect profile and provides recovery in sexual parameters that can be measured with IIEF-15 parameters.

Keywords: Alprostadil, erectile dysfunction, intracavernosal treatment.


ABSTRACT

Objective: In patients treated through the application of intracavernosal alprostadil in sec-ond-line treatment due to erectile dysfunction, the effect of the treatment on sexual functions measured with a 15-question International Index of Erectile Function (IIEF-15) questionnaire was investigated in this study.

Material and Methods: Twenty-one patients treated due to erectile dysfunction between June 2018-October 2019, taking inadequate response from first-line treatment modalities, were applied intracavernosal alprostadil in second-line treat-ment and continued it for more than 12 weeks were included in the study, retrospectively. Ages, comorbid diseases, drug usage duration, drug-re-lated side effects, penile Doppler ultrasonography (USG) parameters before application and the erec-tion functions before and 12 weeks after drug use were evaluated with IIEF-15 form for the patients. Intracavernosal alprostadil was started with a dose of 5 μg and was continued with a dose of 10 μg as the result of dose titration.

Results: The mean peak systolic blood flow velocity (PS) value of the patients was 24.4 ±15.1 cm/sec, and the mean end-diastolic flow veloc-ity (ED) value was measured as 4.3±4.5 cm/sec based on the pre-treatment penile Doppler USG. Although the IIEF scores were measured in the 12th week, mean drug usage durations were mea-sured as 21.9±16.6 weeks. Erectile Function Score was 9.2±5.3 before application; it was detected as 20.33±6.2 after the application. Orgasmic Func-tion Score was 3.2±2.5 before application; it was detected as 7.5±2.4 after the application. Sexual Desire Score was 3.72±1.48 before application; it was detected as 8.9±1.4 after the application. Intercourse Satisfaction Score was 3.7±2.8 before appli-cation; it was detected as 9.1±2.7 after the application. Overall Satis-faction Score was 4±1.7 before application; it was detected as 8.1±1.7 after the application (All parameters p<0.001).

Conclusion: Intracavernosal alprostadil treatment used in erectile dysfunction second-line treatment is a cost-effective and efficient treatment method with a tolerable side effect profile and provides recovery in sexual parameters that can be measured with IIEF-15 parameters.

Keywords: Alprostadil, erectile dysfunction, intracavernosal treatment.

© 2021 The New Journal of Urology - All Rights Reserved.